New drug combo extends survival with advanced kidney cancer - STAT

New drug combo extends survival with advanced kidney cancer - STAT

STAT Plus: New drug combination extends survival with advanced kidney cancer. It’s poised to enter a competitive treatment market

By ADAM FEUERSTEIN

ADOBE

Patients with advanced kidney cancer benefited from a combination of Opdivo from Bristol Myers Squibb and Cabometyx from Exelixis.

READ MORE